ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Sartan-series Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-37K17178
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Sartan series Drugs Market Research Report 2024
BUY CHAPTERS

Global Sartan-series Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-37K17178
Report
November 2025
Pages:143
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Merck
Sanofi
Pfizer Inc
Bayer
Astrazeneca plc
Daiichi Sankyo
Takeda
Bristol Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals

Sartan-series Drugs Market

The global Sartan-series Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Sartan-series drugs are one of the commonly used clinical antihypertensive drugs, ending with "sartan", such as losartan, valsartan, telmisartan, also known as angiotensin II receptor antagonists or Angiotensin receptor blocker (ARBs). They include irbesartan, valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB.
From a downstream perspective, Hospital Pharmaty accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Sartan-series Drugs leading manufacturers including Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, etc., dominate supply; the top five capture approximately % of global revenue, with Novartis leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Sartan-series Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Sartan-series Drugs Market Report

Report Metric Details
Report Name Sartan-series Drugs Market
Segment by Type
  • Losartan
  • Valsartan
  • Irbesartan
  • Telmisartan
  • Olmesartan
  • Candesartan
  • Sacubitril/valsartan
  • Others
Segment by Application
  • Hospital Pharmaty
  • Retail Pharmacy
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, Abbott, Teva Pharmaceutical, Shenzhen Salubris Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Sartan-series Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Sartan-series Drugs Market report?

Ans: The main players in the Sartan-series Drugs Market are Novartis, Merck & Co, Sanofi, Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Takeda, Bristol-Myers Squibb Company, Boehringer Ingelheim, Abbott, Teva Pharmaceutical, Shenzhen Salubris Pharmaceuticals

What are the Application segmentation covered in the Sartan-series Drugs Market report?

Ans: The Applications covered in the Sartan-series Drugs Market report are Hospital Pharmaty, Retail Pharmacy

What are the Type segmentation covered in the Sartan-series Drugs Market report?

Ans: The Types covered in the Sartan-series Drugs Market report are Losartan, Valsartan, Irbesartan, Telmisartan, Olmesartan, Candesartan, Sacubitril/valsartan, Others

1 Study Coverage
1.1 Introduction to Sartan-series Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Sartan-series Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Losartan
1.2.3 Valsartan
1.2.4 Irbesartan
1.2.5 Telmisartan
1.2.6 Olmesartan
1.2.7 Candesartan
1.2.8 Sacubitril/valsartan
1.2.9 Others
1.3 Market Segmentation by Application
1.3.1 Global Sartan-series Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmaty
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Sartan-series Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Sartan-series Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Sartan-series Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Sartan-series Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Losartan Market Size by Players
3.3.2 Valsartan Market Size by Players
3.3.3 Irbesartan Market Size by Players
3.3.4 Telmisartan Market Size by Players
3.3.5 Olmesartan Market Size by Players
3.3.6 Candesartan Market Size by Players
3.3.7 Sacubitril/valsartan Market Size by Players
3.3.8 Others Market Size by Players
3.4 Global Sartan-series Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Sartan-series Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Sartan-series Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Sartan-series Drugs Market Size by Type (2020-2031)
6.4 North America Sartan-series Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Sartan-series Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Sartan-series Drugs Market Size by Type (2020-2031)
7.4 Europe Sartan-series Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Sartan-series Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Sartan-series Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Sartan-series Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Sartan-series Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Sartan-series Drugs Market Size by Type (2020-2031)
9.4 Central and South America Sartan-series Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Sartan-series Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Sartan-series Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Sartan-series Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Sartan-series Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Business Overview
11.1.3 Novartis Sartan-series Drugs Product Features and Attributes
11.1.4 Novartis Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.1.5 Novartis Sartan-series Drugs Revenue by Product in 2024
11.1.6 Novartis Sartan-series Drugs Revenue by Application in 2024
11.1.7 Novartis Sartan-series Drugs Revenue by Geographic Area in 2024
11.1.8 Novartis Sartan-series Drugs SWOT Analysis
11.1.9 Novartis Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Corporation Information
11.2.2 Merck & Co Business Overview
11.2.3 Merck & Co Sartan-series Drugs Product Features and Attributes
11.2.4 Merck & Co Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Merck & Co Sartan-series Drugs Revenue by Product in 2024
11.2.6 Merck & Co Sartan-series Drugs Revenue by Application in 2024
11.2.7 Merck & Co Sartan-series Drugs Revenue by Geographic Area in 2024
11.2.8 Merck & Co Sartan-series Drugs SWOT Analysis
11.2.9 Merck & Co Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Sartan-series Drugs Product Features and Attributes
11.3.4 Sanofi Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi Sartan-series Drugs Revenue by Product in 2024
11.3.6 Sanofi Sartan-series Drugs Revenue by Application in 2024
11.3.7 Sanofi Sartan-series Drugs Revenue by Geographic Area in 2024
11.3.8 Sanofi Sartan-series Drugs SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Sartan-series Drugs Product Features and Attributes
11.4.4 Pfizer Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.4.5 Pfizer Sartan-series Drugs Revenue by Product in 2024
11.4.6 Pfizer Sartan-series Drugs Revenue by Application in 2024
11.4.7 Pfizer Sartan-series Drugs Revenue by Geographic Area in 2024
11.4.8 Pfizer Sartan-series Drugs SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 Bayer
11.5.1 Bayer Corporation Information
11.5.2 Bayer Business Overview
11.5.3 Bayer Sartan-series Drugs Product Features and Attributes
11.5.4 Bayer Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Bayer Sartan-series Drugs Revenue by Product in 2024
11.5.6 Bayer Sartan-series Drugs Revenue by Application in 2024
11.5.7 Bayer Sartan-series Drugs Revenue by Geographic Area in 2024
11.5.8 Bayer Sartan-series Drugs SWOT Analysis
11.5.9 Bayer Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Sartan-series Drugs Product Features and Attributes
11.6.4 AstraZeneca Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.6.5 AstraZeneca Recent Developments
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Corporation Information
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Sartan-series Drugs Product Features and Attributes
11.7.4 Daiichi Sankyo Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Daiichi Sankyo Recent Developments
11.8 Takeda
11.8.1 Takeda Corporation Information
11.8.2 Takeda Business Overview
11.8.3 Takeda Sartan-series Drugs Product Features and Attributes
11.8.4 Takeda Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.8.5 Takeda Recent Developments
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Corporation Information
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Sartan-series Drugs Product Features and Attributes
11.9.4 Bristol-Myers Squibb Company Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.9.5 Bristol-Myers Squibb Company Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Corporation Information
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Sartan-series Drugs Product Features and Attributes
11.10.4 Boehringer Ingelheim Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Abbott
11.11.1 Abbott Corporation Information
11.11.2 Abbott Business Overview
11.11.3 Abbott Sartan-series Drugs Product Features and Attributes
11.11.4 Abbott Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.11.5 Abbott Recent Developments
11.12 Teva Pharmaceutical
11.12.1 Teva Pharmaceutical Corporation Information
11.12.2 Teva Pharmaceutical Business Overview
11.12.3 Teva Pharmaceutical Sartan-series Drugs Product Features and Attributes
11.12.4 Teva Pharmaceutical Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.12.5 Teva Pharmaceutical Recent Developments
11.13 Shenzhen Salubris Pharmaceuticals
11.13.1 Shenzhen Salubris Pharmaceuticals Corporation Information
11.13.2 Shenzhen Salubris Pharmaceuticals Business Overview
11.13.3 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Product Features and Attributes
11.13.4 Shenzhen Salubris Pharmaceuticals Sartan-series Drugs Revenue and Gross Margin (2020-2025)
11.13.5 Shenzhen Salubris Pharmaceuticals Recent Developments
12 Sartan-series DrugsIndustry Chain Analysis
12.1 Sartan-series Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Sartan-series Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Sartan-series Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Novartis
Merck
Sanofi
Pfizer Inc
Bayer
Astrazeneca plc
Daiichi Sankyo
Takeda
Bristol Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
List of Tables
 Table 1. Global Sartan-series Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Sartan-series Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Sartan-series Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Sartan-series Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Sartan-series Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Sartan-series Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Sartan-series Drugs Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Sartan-series Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sartan-series Drugs as of 2024)
 Table 11. Global Sartan-series Drugs Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Sartan-series Drugs Companies Headquarters
 Table 13. Global Sartan-series Drugs Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Sartan-series Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Sartan-series Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Sartan-series Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Sartan-series Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Sartan-series Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Sartan-series Drugs Growth Accelerators and Market Barriers
 Table 25. North America Sartan-series Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Sartan-series Drugs Growth Accelerators and Market Barriers
 Table 27. Europe Sartan-series Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Sartan-series Drugs Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Sartan-series Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Sartan-series Drugs Investment Opportunities and Key Challenges
 Table 31. Central and South America Sartan-series Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Sartan-series Drugs Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Sartan-series Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Novartis Corporation Information
 Table 35. Novartis Description and Major Businesses
 Table 36. Novartis Product Features and Attributes
 Table 37. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Novartis Revenue Proportion by Product in 2024
 Table 39. Novartis Revenue Proportion by Application in 2024
 Table 40. Novartis Revenue Proportion by Geographic Area in 2024
 Table 41. Novartis Sartan-series Drugs SWOT Analysis
 Table 42. Novartis Recent Developments
 Table 43. Merck & Co Corporation Information
 Table 44. Merck & Co Description and Major Businesses
 Table 45. Merck & Co Product Features and Attributes
 Table 46. Merck & Co Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Merck & Co Revenue Proportion by Product in 2024
 Table 48. Merck & Co Revenue Proportion by Application in 2024
 Table 49. Merck & Co Revenue Proportion by Geographic Area in 2024
 Table 50. Merck & Co Sartan-series Drugs SWOT Analysis
 Table 51. Merck & Co Recent Developments
 Table 52. Sanofi Corporation Information
 Table 53. Sanofi Description and Major Businesses
 Table 54. Sanofi Product Features and Attributes
 Table 55. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Sanofi Revenue Proportion by Product in 2024
 Table 57. Sanofi Revenue Proportion by Application in 2024
 Table 58. Sanofi Revenue Proportion by Geographic Area in 2024
 Table 59. Sanofi Sartan-series Drugs SWOT Analysis
 Table 60. Sanofi Recent Developments
 Table 61. Pfizer Corporation Information
 Table 62. Pfizer Description and Major Businesses
 Table 63. Pfizer Product Features and Attributes
 Table 64. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Pfizer Revenue Proportion by Product in 2024
 Table 66. Pfizer Revenue Proportion by Application in 2024
 Table 67. Pfizer Revenue Proportion by Geographic Area in 2024
 Table 68. Pfizer Sartan-series Drugs SWOT Analysis
 Table 69. Pfizer Recent Developments
 Table 70. Bayer Corporation Information
 Table 71. Bayer Description and Major Businesses
 Table 72. Bayer Product Features and Attributes
 Table 73. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Bayer Revenue Proportion by Product in 2024
 Table 75. Bayer Revenue Proportion by Application in 2024
 Table 76. Bayer Revenue Proportion by Geographic Area in 2024
 Table 77. Bayer Sartan-series Drugs SWOT Analysis
 Table 78. Bayer Recent Developments
 Table 79. AstraZeneca Corporation Information
 Table 80. AstraZeneca Description and Major Businesses
 Table 81. AstraZeneca Product Features and Attributes
 Table 82. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. AstraZeneca Recent Developments
 Table 84. Daiichi Sankyo Corporation Information
 Table 85. Daiichi Sankyo Description and Major Businesses
 Table 86. Daiichi Sankyo Product Features and Attributes
 Table 87. Daiichi Sankyo Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Daiichi Sankyo Recent Developments
 Table 89. Takeda Corporation Information
 Table 90. Takeda Description and Major Businesses
 Table 91. Takeda Product Features and Attributes
 Table 92. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Takeda Recent Developments
 Table 94. Bristol-Myers Squibb Company Corporation Information
 Table 95. Bristol-Myers Squibb Company Description and Major Businesses
 Table 96. Bristol-Myers Squibb Company Product Features and Attributes
 Table 97. Bristol-Myers Squibb Company Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb Company Recent Developments
 Table 99. Boehringer Ingelheim Corporation Information
 Table 100. Boehringer Ingelheim Description and Major Businesses
 Table 101. Boehringer Ingelheim Product Features and Attributes
 Table 102. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Boehringer Ingelheim Recent Developments
 Table 104. Abbott Corporation Information
 Table 105. Abbott Description and Major Businesses
 Table 106. Abbott Product Features and Attributes
 Table 107. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. Abbott Recent Developments
 Table 109. Teva Pharmaceutical Corporation Information
 Table 110. Teva Pharmaceutical Description and Major Businesses
 Table 111. Teva Pharmaceutical Product Features and Attributes
 Table 112. Teva Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 113. Teva Pharmaceutical Recent Developments
 Table 114. Shenzhen Salubris Pharmaceuticals Corporation Information
 Table 115. Shenzhen Salubris Pharmaceuticals Description and Major Businesses
 Table 116. Shenzhen Salubris Pharmaceuticals Product Features and Attributes
 Table 117. Shenzhen Salubris Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 118. Shenzhen Salubris Pharmaceuticals Recent Developments
 Table 119. Raw Materials Key Suppliers
 Table 120. Distributors List
 Table 121. Market Trends and Market Evolution
 Table 122. Market Drivers and Opportunities
 Table 123. Market Challenges, Risks, and Restraints
 Table 124. Research Programs/Design for This Report
 Table 125. Key Data Information from Secondary Sources
 Table 126. Key Data Information from Primary Sources


List of Figures
 Figure 1. Sartan-series Drugs Product Picture
 Figure 2. Global Sartan-series Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Losartan Product Picture
 Figure 4. Valsartan Product Picture
 Figure 5. Irbesartan Product Picture
 Figure 6. Telmisartan Product Picture
 Figure 7. Olmesartan Product Picture
 Figure 8. Candesartan Product Picture
 Figure 9. Sacubitril/valsartan Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global Sartan-series Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Hospital Pharmaty
 Figure 13. Retail Pharmacy
 Figure 14. Sartan-series Drugs Report Years Considered
 Figure 15. Global Sartan-series Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 17. Global Sartan-series Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 18. Global Sartan-series Drugs Revenue Market Share by Region (2020-2031)
 Figure 19. Global Sartan-series Drugs Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. Losartan Revenue Market Share by Player in 2024
 Figure 22. Valsartan Revenue Market Share by Player in 2024
 Figure 23. Irbesartan Revenue Market Share by Player in 2024
 Figure 24. Telmisartan Revenue Market Share by Player in 2024
 Figure 25. Olmesartan Revenue Market Share by Player in 2024
 Figure 26. Candesartan Revenue Market Share by Player in 2024
 Figure 27. Sacubitril/valsartan Revenue Market Share by Player in 2024
 Figure 28. Others Revenue Market Share by Player in 2024
 Figure 29. Global Sartan-series Drugs Revenue Market Share by Type (2020-2031)
 Figure 30. Global Sartan-series Drugs Revenue Market Share by Application (2020-2031)
 Figure 31. North America Sartan-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 32. North America Top 5 Players Sartan-series Drugs Revenue (US$ Million) in 2024
 Figure 33. North America Sartan-series Drugs Revenue (US$ Million) by Type (2020 - 2031)
 Figure 34. North America Sartan-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 35. US Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 36. Canada Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 37. Mexico Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 38. Europe Sartan-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Europe Top 5 Players Sartan-series Drugs Revenue (US$ Million) in 2024
 Figure 40. Europe Sartan-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Europe Sartan-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 43. France Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Sartan-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 48. Asia-Pacific Top 8 Players Sartan-series Drugs Revenue (US$ Million) in 2024
 Figure 49. Asia-Pacific Sartan-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 50. Asia-Pacific Sartan-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 51. Indonesia Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 52. Japan Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 53. South Korea Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 54. Australia Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 55. India Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 56. Indonesia Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 57. Vietnam Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 58. Malaysia Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 59. Philippines Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 60. Singapore Sartan-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 61. Central and South America Sartan-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 62. Central and South America Top 5 Players Sartan-series Drugs Revenue (US$ Million) in 2024
 Figure 63. Central and South America Sartan-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Sartan-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 65. Brazil Sartan-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 66. Argentina Sartan-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 67. Middle East and Africa Sartan-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 68. Middle East and Africa Top 5 Players Sartan-series Drugs Revenue (US$ Million) in 2024
 Figure 69. South America Sartan-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 70. Middle East and Africa Sartan-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 71. GCC Countries Sartan-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 72. Israel Sartan-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 73. Egypt Sartan-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 74. South Africa Sartan-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 75. Sartan-series Drugs Industry Chain Mapping
 Figure 76. Channels of Distribution (Direct Vs Distribution)
 Figure 77. Bottom-up and Top-down Approaches for This Report
 Figure 78. Data Triangulation
 Figure 79. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Angiotensin II Receptor Blocker ARBs API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Irbesartan Market Research Report 2024
Angiotensin Receptor Blockers ARBs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Valsartan Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Sartans Market Research Report 2024
Global Irbesartan Tablets Market Insights Forecast to 2030
Global Valsartan Capsules Market Research Report 2024
Valsartan Hydrochlorothiazide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Valsartan Tablets Market Research Report 2024
Global Telmisartan Tablet Market Research Report 2024
lrbesartan Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Telmisartan Dispersible Tablets Market Research Report 2024
Global Irbesartan Amlodipine Tablets Market Research Report 2024
Angiotensin Receptor Antagonists Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Renin Angiotensin System RAS Inhibitor Market Research Report 2024
Candesartan Cilexetil Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Candesartan and Hydrochlorothiazide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Telmisartan and Hydrochlorothiazide Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pril series Drugs API Market Research Report 2024
Global Irbesartan API Market Research Report 2024

RELATED REPORTS

Global Levothyroxine Sodium Tablets Hormone Medication Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-25N19924
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Needle Free Allergy Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24B19783
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Hydrotalcite Antacid Chewable Tablets Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20305
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Dual Orexin Receptor Antagonist Sleeping Pills Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12S20176
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions